Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2021 | P10015/SARC033: trametinib in advanced EHE

Robin Jones, MBBS, MRCP, MD, Royal Marsden NHS Foundation Trust, London, UK, discusses the results from the P10015/SARC033 trial: a Phase II single-arm prospective trial of trametinib in advanced epithelioid hemangioendothelioma (EHE) (NCT03148275); this was the largest prospective trial of this cancer subtype with (n=42). No unexpected safety signals were found, the overall response rate (ORR) was 7%, the median progression free survival (mPFS) was 8.2 months, patients exhibited tumor shrinkage, and the pain outcome measures of patients was improved. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.